San Diego, Feb. 13, 2012 (Shareholders Foundation) -- An investigation on behalf of investors in shares of Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) was announced over potential securities laws violations by certain officers and directors at Chelsea Therapeutics Intl in connection with potentially false and misleading statements.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Chelsea Therapeutics International (NASDAQ:CHTP) concerning whether a series of statements regarding Chelsea Therapeutics business, its prospects and its operations were materially false and misleading at the time they were made.

NASDAQ: CHTP shares spiked from as low as $1.20 per share in December 2008 to as high $6.90 in September 2009 and again from as low as $2.58 in January 2010 to as high as $7.84 in January 2011.
For the most part of 2011 shares of Chelsea Therapeutics International Ltd. were able to hold for value above $4 per share and closed 2011 at slightly above $5 per share.

Then on February 13, 2012, Chelsea Therapeutics International, Ltd issued a press release stating, in part, that it had received the U.S. Food and Drug Administration (FDA) briefing document in advance of the upcoming Cardiovascular and Renal Drugs Advisory Committee meeting scheduled for February 23, 2012. Chelsea Therapeutics International further stated that it was updating shareholders on several lines of inquiry that have emerged as significant components of the benefit-risk analysis by the FDA, including the short duration of [Chelsea Therapeutics] clinical studies, the limited size of [Chelsea Therapeutics] study population given the orphan indication and the challenges in quantifying symptomatic and clinical benefit.

NASDAQ:CHTP shares dropped from almost $5 on February 10, 2012 to $3 per share on Monday, February 13, 2012.